The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program
Anthony Elias(University of Colorado Cancer Center), Paul G. Richardson(Harvard University), E Reich(Harvard University), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Joseph G. Ibrahim(University of North Carolina at Chapel Hill), Catherine Wheeler(Harvard University), Mary McCauley(Harvard University)
Cited by 16
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k